{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T19:03:30Z","timestamp":1792955010531,"version":"4.5.0"},"reference-count":216,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":6038,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular &amp; Cellular Proteomics"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1074\/mcp.r400001-mcp200","type":"journal-article","created":{"date-parts":[[2004,2,9]],"date-time":"2004-02-09T20:12:51Z","timestamp":1076357571000},"page":"379-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":235,"title":["Targeted Therapy in Breast Cancer"],"prefix":"10.1016","volume":"3","author":[{"given":"Jeffrey S.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald P.","family":"Linette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Fraser","family":"Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/mcp.R400001-MCP200_bib1","first-page":"237","article-title":"EGFR family signaling and its association with breast cancer development and resistance to chemotherapy.","volume":"22","author":"Navolanic","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/j.1460-2075.1996.tb00356.x","article-title":"ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer.","volume":"15","author":"Karunagaran","year":"1996","journal-title":"EMBO J."},{"key":"10.1074\/mcp.R400001-MCP200_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network.","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1074\/mcp.R400001-MCP200_bib4","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor.","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"10.1074\/mcp.R400001-MCP200_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0960-7404(03)00004-5","article-title":"A decade of tyrosine kinases: From gene discovery to therapeutics.","volume":"12","author":"Craven","year":"2003","journal-title":"Surg. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib6","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/1097-0142(19940201)73:3<652::AID-CNCR2820730324>3.0.CO;2-4","article-title":"Elevated erb B-2 oncoprotein levels in preoperative and follow-up serum samples defined in aggressive course in patients with breast cancer.","volume":"73","author":"Isola","year":"1994","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/02841869509094014","article-title":"Detection of C-erb B2 related proteins in sera from breast cancer patients. Relationship to ERBB2 gene amplification and Cerb B2 protein overexpression in tumour.","volume":"34","author":"Andersen","year":"1995","journal-title":"Acta Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF01806813","article-title":"Prognostic significance of serum CerbB2 protein in breast cancer patients.","volume":"40","author":"Willsher","year":"1996","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1074\/mcp.R400001-MCP200_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1005700812422","article-title":"Influence of circulating C-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients.","volume":"43","author":"Fehm","year":"1997","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1074\/mcp.R400001-MCP200_bib10","first-page":"3101","article-title":"Tissue in serum CerbB2 and tissue EGFR in breast carcinoma: Three years follow-up.","volume":"17","author":"Mansour","year":"1997","journal-title":"Anticancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib11","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.1997.15.11.3363","article-title":"High-titer HER-2\/neu protein-specific antibody can be detected in patients with early-stage breast cancer.","volume":"15","author":"Disis","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1074\/mcp.R400001-MCP200_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000227606","article-title":"Tissue expression and serum levels of HER-2\/neu in patients with breast cancer.","volume":"54","author":"Krainer","year":"1997","journal-title":"Oncology"},{"key":"10.1074\/mcp.R400001-MCP200_bib13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<874::AID-CNCR11>3.0.CO;2-Y","article-title":"Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma.","volume":"82","author":"Burke","year":"1998","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000011832","article-title":"The prognostic significance of c erbB-2 serum protein in metastatic breast cancer.","volume":"55","author":"Fehm","year":"1998","journal-title":"Oncology"},{"key":"10.1074\/mcp.R400001-MCP200_bib15","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1200\/JCO.1998.16.7.2409","article-title":"Plasma c-erbB-2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy.","volume":"16","author":"Mehta","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib16","first-page":"2356","article-title":"Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.","volume":"6","author":"Colomer","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/sj.bmt.1703005","article-title":"HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.","volume":"27","author":"Bewick","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1074\/mcp.R400001-MCP200_bib18","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2001.19.6.1698","article-title":"Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy.","volume":"19","author":"Harris","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib19","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/clinchem\/48.8.1314","article-title":"Relationship of serum HER-2\/neu and serum CA 15-3 in patients with metastatic breast cancer.","volume":"48","author":"Ali","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1074\/mcp.R400001-MCP200_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000059706","article-title":"Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.","volume":"23","author":"Classen","year":"2002","journal-title":"Tumour Biol."},{"key":"10.1074\/mcp.R400001-MCP200_bib21","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2002.20.6.1467","article-title":"Elevated serum Her-2\/neu level predicts decreased response to hormone therapy in metastatic breast cancer.","volume":"20","author":"Lipton","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/bjc.1994.387","article-title":"Soluble c-erb B-2 fragments in serum correlates with disease stage and predicts more shortened survival in patients with early-stage and advanced breast cancer.","volume":"70","author":"Kandl","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<267::AID-CNCR12>3.0.CO;2-U","article-title":"Serial serum C-erbB-2 levels in patients with breast carcinoma.","volume":"78","author":"Volas","year":"1996","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib24","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1373\/49.10.1579","article-title":"Potential clinical utility of serum HER-2\/neu oncoprotein concentrations in patients with breast cancer.","volume":"49","author":"Carney","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1074\/mcp.R400001-MCP200_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0959-8049(95)00568-4","article-title":"Plasma CerbB2 concentrations in relations to chemotherapy in breast cancer patients.","volume":"32a","author":"Revillion","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib26","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/clinchem\/48.8.1314","article-title":"Relationship of serum HER-2\/neu and serum CA 15-3 in patients with metastatic breast cancer.","volume":"48","author":"Ali","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1074\/mcp.R400001-MCP200_bib27","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.2003.09.098","article-title":"Serum HER-2\/neu and response to the aromatase inhibitor letrozole versus tamoxifen.","volume":"21","author":"Lipton","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CBC.2002.n.017","article-title":"The HER2 extracellular domain as a prognostic and predictive factor in breast cancer.","volume":"3","author":"Nunes","year":"2002","journal-title":"Clin. Breast Cancer."},{"key":"10.1074\/mcp.R400001-MCP200_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0093-7754(01)90188-5","article-title":"Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.","volume":"28","author":"Slamon","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib30","first-page":"81","article-title":"Immunophenotype of intraductal carcinoma.","volume":"120","author":"Bose","year":"1996","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1074\/mcp.R400001-MCP200_bib31","first-page":"1088","article-title":"Ductal carcinoma in-situ of the breast: Correlation between histologic classification and biologic markers.","volume":"10","author":"Moreno","year":"1997","journal-title":"Mod. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0046-8177(97)90014-9","article-title":"Relationship of a new histological categorization of ductal carcinoma in-situ of the breast with size and the immunohistochemical expression of p53, C-erb B2, bcl2 and ki-67.","volume":"28","author":"Mack","year":"1997","journal-title":"Hum. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00129039-200203000-00007","article-title":"Comparison of HER-2\/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.","volume":"10","author":"Rosenthal","year":"2002","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1074\/mcp.R400001-MCP200_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ajcp\/96.2.243","article-title":"Expression of cerb B2 oncoprotein in mammary and extramammary Paget\u2019s disease.","volume":"96","author":"Wolber","year":"1991","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jso.1090","article-title":"Molecular markers in Paget disease of the breast.","volume":"77","author":"Fu","year":"2001","journal-title":"J. Surg. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1524-4741.2003.09610.x","article-title":"The role of HER-2\/neu oncogene and vimentin filaments in the production of the Paget\u2019s phenotype.","volume":"9","author":"Hanna","year":"2003","journal-title":"Breast J."},{"key":"10.1074\/mcp.R400001-MCP200_bib37","first-page":"259","article-title":"Assessment of Her-2\/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study.","volume":"30","author":"Masood","year":"2000","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1074\/mcp.R400001-MCP200_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/172460080101600406","article-title":"Evaluation of HER-2\/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay.","volume":"16","author":"Dittadi","year":"2001","journal-title":"Int. J. Biol. Markers"},{"key":"10.1074\/mcp.R400001-MCP200_bib39","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/jnci\/93.15.1141","article-title":"Patterns of her-2\/neu amplification and overexpression in primary and metastatic breast cancer.","volume":"93","author":"Simon","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1074\/mcp.R400001-MCP200_bib40","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.10456","article-title":"HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.","volume":"94","author":"Vincent-Salomon","year":"2002","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/modpathol.3880503","article-title":"Amplification of Her-2\/neu gene in Her-2\/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.","volume":"15","author":"Xu","year":"2002","journal-title":"Mod. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0046-8177(95)90039-X","article-title":"Breast cancer heterogeneity: Evaluation of clonality in primary and metastatic lesions.","volume":"26","author":"Symmans","year":"1995","journal-title":"Hum. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/106689699500200305","article-title":"Prognostic factors for carcinoma of the male breast.","volume":"2","author":"Gattuso","year":"1995","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-#","article-title":"Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome.","volume":"77","author":"Joshi","year":"1996","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib45","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.2000.18.16.2948","article-title":"Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.","volume":"18","author":"Pich","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib46","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.MP.0000022251.61944.1D","article-title":"Male breast carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.","volume":"15","author":"Wang-Rodriguez","year":"2002","journal-title":"Mod. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib47","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1947::AID-CNCR10>3.0.CO;2-J","article-title":"Molecular markers in male breast carcinoma.","volume":"83","author":"Rayson","year":"1998","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1096-9098(200012)75:4<252::AID-JSO5>3.0.CO;2-2","article-title":"Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer.","volume":"75","author":"Shpitz","year":"2000","journal-title":"J. Surg. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0002-9610(01)00733-4","article-title":"Status of HER-2 in male and female breast carcinoma.","volume":"182","author":"Bloom","year":"2001","journal-title":"Am. J. Surg."},{"key":"10.1074\/mcp.R400001-MCP200_bib50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JCO.2000.18.2.267","article-title":"HER-2\/neu amplification in benign breast disease and the risk of subsequent breast cancer.","volume":"18","author":"Stark","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib51","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/sonc.2002.32899","article-title":"c-erbB-2 in breast cancer: Development of a clinically useful marker.","volume":"29","author":"Hayes","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib52","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jemt.10181","article-title":"Prognostic and predictive value of HER2\/neu oncogene in breast cancer.","volume":"59","author":"Masood","year":"2002","journal-title":"Microsc. Res. Tech."},{"key":"10.1074\/mcp.R400001-MCP200_bib53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1023\/A:1014730829872","article-title":"The role of c-erbB-2\/HER2\/neu in breast cancer progression and metastasis.","volume":"6","author":"Eccles","year":"2001","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"issue":"Suppl. 2","key":"10.1074\/mcp.R400001-MCP200_bib54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000055405","article-title":"The predictive value of HER2 in breast cancer.","volume":"61","author":"Piccart","year":"2001","journal-title":"Oncology"},{"issue":"Suppl. 2","key":"10.1074\/mcp.R400001-MCP200_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000055396","article-title":"Biology of HER2 and its importance in breast cancer.","volume":"61","author":"Yarden","year":"2001","journal-title":"Oncology"},{"key":"10.1074\/mcp.R400001-MCP200_bib56","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.2003.04.170","article-title":"Invasion factors uPA\/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.","volume":"21","author":"Zemzoum","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib57","first-page":"1946","article-title":"Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu\/erbB-2 in a subset of human breast tumors overexpressing this receptor.","volume":"55","author":"DiGiovanna","year":"1995","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib58","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1200\/JCO.2000.18.18.3230","article-title":"Activation (tyrosine phosphorylation) of ErbB-2 (HER-2\/neu): A study of incidence and correlation with outcome in breast cancer.","volume":"18","author":"Thor","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib59","first-page":"6667","article-title":"Active signaling by HER-2\/neu in a subpopulation of HER-2\/neu-overexpressing ductal carcinoma in situ: Clinicopathological correlates.","volume":"62","author":"DiGiovanna","year":"2002","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib60","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the Her-2\/neu oncogene.","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1074\/mcp.R400001-MCP200_bib61","first-page":"1238","article-title":"Correlation of c-erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.","volume":"48","author":"Berger","year":"1988","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib62","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJM198811103191902","article-title":"Neu-protein overexpression in breast cancer.","volume":"319","author":"van de Vivjer","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1074\/mcp.R400001-MCP200_bib63","first-page":"160","article-title":"Amplification of the c-erb B 2 oncogene in prognosis of breast adenocarcinoma.","volume":"114","author":"Heintz","year":"1990","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1074\/mcp.R400001-MCP200_bib64","first-page":"2087","article-title":"Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer.","volume":"49","author":"Wright","year":"1989","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib65","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/1097-0142(19900415)65:8<1794::AID-CNCR2820650821>3.0.CO;2-Y","article-title":"Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases.","volume":"65","author":"Tsuda","year":"1990","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib66","first-page":"4332","article-title":"HER-2\/neu amplification predicts poor survival in node-positive breast cancer.","volume":"50","author":"Borg","year":"1990","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib67","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1990.8.1.103","article-title":"Pathologic findings from the nations surgical adjuvant breast and bowel project: Prognostic significance of erb B2 protein overexpression in primary breast cancer.","volume":"8","author":"Paik","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib68","first-page":"466","article-title":"Immunohistochemical assay of neu\/c-erb B-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases.","volume":"4","author":"Battifora","year":"1991","journal-title":"Mod. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib69","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ijc.2910490504","article-title":"Association of C-erb B2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.","volume":"49","author":"Kallioniemi","year":"1991","journal-title":"Int. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib70","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bjc.1991.100","article-title":"c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.","volume":"63","author":"Gullick","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib71","first-page":"944","article-title":"Follow-up study of HER-2\/neu amplification in primary breast cancer.","volume":"51","author":"Clark","year":"1991","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib72","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/bjc.1991.101","article-title":"C-erb B2 oncoprotein expression in primary and advanced breast cancer.","volume":"63","author":"Lovekin","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib73","first-page":"3296","article-title":"Prognostic significance of C-erb B2 and estrogen receptor status in human breast cancer.","volume":"51","author":"McCann","year":"1991","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/path.1711630205","article-title":"Long term survival in breast cancer related to overexpression of the C-erb B2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11.","volume":"163","author":"Dykens","year":"1991","journal-title":"J. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib75","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ijc.2910490109","article-title":"Prognostic significance of HER-2\/neu expression in breast cancer and its relationship to other prognostic factors.","volume":"49","author":"Rilke","year":"1991","journal-title":"Int. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib76","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/bjc.1991.103","article-title":"The long term prognostic significance of C-erb B2 in primary breast cancer.","volume":"63","author":"Winstanley","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib77","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/bjc.1991.102","article-title":"The relationship between C-erb B2 expression, and s-phase fraction in prognosis in breast cancer.","volume":"63","author":"O\u2019Reilly","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib78","first-page":"556","article-title":"Correlation between C erb B2 amplification and risk of recurrent disease in node-negative breast cancer.","volume":"51","author":"Paterson","year":"1991","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib79","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.1992.10.7.1044","article-title":"Prognostic significance of Her-2 oncoprotein expression in breast cancer: A 30-year follow up.","volume":"10","author":"Toikkanen","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib80","first-page":"1965","article-title":"Expression of HER-2\/neu oncoprotein in breast cancer: A comparison of immunohistochemical and western blot techniques.","volume":"12","author":"Molina","year":"1992","journal-title":"Anticancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib81","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/1097-0142(19920615)69:12<2953::AID-CNCR2820691214>3.0.CO;2-U","article-title":"c-erb B-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer.","volume":"69","author":"Noguchi","year":"1992","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib82","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.1992.10.4.599","article-title":"HER-2\/neu node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in-situ carcinoma.","volume":"10","author":"Allred","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib83","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/1097-0142(19920815)70:4<770::AID-CNCR2820700409>3.0.CO;2-U","article-title":"Significance of c-erb B-2 amplification in DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer.","volume":"70","author":"Babiak","year":"1992","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib84","first-page":"419","article-title":"HER-2\/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.","volume":"12","author":"Tiwari","year":"1992","journal-title":"Anticancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib85","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.1992.10.7.1049","article-title":"Prognostic importance of C-erb B2 expression in breast cancer.","volume":"10","author":"Gusterson","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib86","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/bjc.1993.114","article-title":"Prognostic significance of C-erb B2 expression in node negative breast cancer.","volume":"67","author":"Bianchi","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib87","first-page":"4960","article-title":"Her-2\/neu expression in node-negative breast cancer: Direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease.","volume":"53","author":"Press","year":"1993","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib88","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.1993.11.10.1936","article-title":"Clinical significance of Her-2\/neu oncogene amplification in primary breast cancer.","volume":"11","author":"Seshadri","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib89","first-page":"119","article-title":"Human breast cancer: Correlation study between Her-2\/neu amplification and prognostic factors in an unselected population.","volume":"13","author":"Descotes","year":"1993","journal-title":"Anticancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib90","first-page":"1441","article-title":"Prognostic and predictive relevance of C-erb B2 and ras expression in node positive and negative breast cancer.","volume":"14","author":"Giai","year":"1994","journal-title":"Anticancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib91","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199405053301802","article-title":"Cerb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer.","volume":"330","author":"Muss","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1074\/mcp.R400001-MCP200_bib92","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9","article-title":"Prognostic significance of Her-2\/neu oncogene expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy.","volume":"73","author":"Tetu","year":"1994","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib93","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V","article-title":"Prognostic value of CerbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol.","volume":"74","author":"Hartmann","year":"1994","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib94","first-page":"2773","article-title":"Breast cancer response to adjuvant chemotherapy in correlation with erb B2 and p53 expression.","volume":"14","author":"Jacquemeier","year":"1994","journal-title":"Anticancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib95","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00000658-199404000-00002","article-title":"Overexpression of p53 and Her 2\/neu proteins as prognostic markers in early stage breast cancer.","volume":"219","author":"Marks","year":"1994","journal-title":"Ann. Surg."},{"key":"10.1074\/mcp.R400001-MCP200_bib96","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/1097-0142(19950315)75:6<1320::AID-CNCR2820750614>3.0.CO;2-C","article-title":"Immunohistochemical detection of Her-2\/neu expression in patients with axillary lymph node-negative breast carcinoma. A study of epidemiologic risk factors, histologic features and prognosis.","volume":"75","author":"Rosen","year":"1995","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib97","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00665980","article-title":"The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases.","volume":"35","author":"Quenel","year":"1995","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1074\/mcp.R400001-MCP200_bib98","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0046-8177(96)90072-6","article-title":"Carcinoembryonic expression in stages I and II breast cancer; its relationship with clinicopathologic factors.","volume":"27","author":"Sundblad","year":"1996","journal-title":"Hum. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib99","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0046-8177(96)90224-5","article-title":"The predictive power of semiquantitative immunohistochemical assessment of p53 and C-erbB2 in lymph node-negative breast cancer.","volume":"27","author":"O\u2019Malley","year":"1996","journal-title":"Hum. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib100","first-page":"A113","article-title":"Her-2\/neu and p53 expression in breast cancer: Valid prognostic markers when assessed by direct immunoassay, but not by immunochemistry.","volume":"15","author":"Hieken","year":"1996","journal-title":"Proc. Annu. Meet. Am. Soc. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib101","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF01806187","article-title":"FISH detection of HER-2\/neu oncogene amplification in early onset breast cancer.","volume":"39","author":"Xing","year":"1996","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1074\/mcp.R400001-MCP200_bib102","first-page":"1245","article-title":"ErbB2 assay in breast cancer: Possibly improved clinical information using a quantitative method.","volume":"17","author":"Dittadi","year":"1997","journal-title":"Anticancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib103","first-page":"289","article-title":"Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: Relation with epidemiologic factors, histologic features and prognosis.","volume":"142","author":"Fernandez Acenero","year":"1997","journal-title":"Gen. Diagn. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib104","first-page":"3091","article-title":"Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.","volume":"17","author":"Eissa","year":"1997","journal-title":"Anticancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib105","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/bjc.1997.283","article-title":"c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients\u2019 overall and disease-free survival.","volume":"75","author":"Charpin","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib106","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","article-title":"Her-2\/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node negative breast carcinomas.","volume":"15","author":"Press","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib107","first-page":"26A","article-title":"Multivariate analysis of prognostic factors in lymph node negative breast cancer.","volume":"11","author":"Ross","year":"1998","journal-title":"Mod. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib108","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/ajcp\/112.4.459","article-title":"Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2\/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.","volume":"112","author":"Depowski","year":"1999","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<89::AID-CNCR12>3.0.CO;2-8","article-title":"Modulation of biomarkers in minimal breast carcinoma.","volume":"83","author":"Querzoli","year":"1998","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib110","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.1998.16.4.1340","article-title":"Neu\/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer.","volume":"16","author":"Andrulis","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib111","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JCO.1998.16.2.462","article-title":"Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.","volume":"16","author":"Sjogren","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib112","first-page":"663","article-title":"HER-2\/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.","volume":"14","author":"Harbeck","year":"1999","journal-title":"Int. J. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib113","first-page":"815","article-title":"Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis.","volume":"5","author":"Scorilas","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib114","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<207::AID-PATH223>3.0.CO;2-U","article-title":"Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications.","volume":"187","author":"Rudolph","year":"1999","journal-title":"J. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib115","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-Y","article-title":"The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: A multivariate analysis of prognostic factors in 613 patients with a follow-up of 14\u201330 years.","volume":"88","author":"Reed","year":"2000","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib116","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","article-title":"Assessment of methods for tissue-based detection of the HER-2\/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry.","volume":"18","author":"Pauletti","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib117","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF03262077","article-title":"HER-2\/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survival.","volume":"5","author":"Kakar","year":"2000","journal-title":"Mol. Diagn."},{"key":"10.1074\/mcp.R400001-MCP200_bib118","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1023\/A:1006498721508","article-title":"C-erbB-2 overexpression and survival in early onset breast cancer.","volume":"63","author":"Agrup","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1074\/mcp.R400001-MCP200_bib119","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1097-0215(20001120)89:6<484::AID-IJC3>3.0.CO;2-S","article-title":"Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients.","volume":"89","author":"Umekita","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib120","first-page":"4217","article-title":"Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.","volume":"6","author":"Pawlowski","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib121","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1006464426977","article-title":"Prognostic significance of biologic markers in node-negative breast cancer patients: A prospective study.","volume":"63","author":"Volpi","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1074\/mcp.R400001-MCP200_bib122","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archsurg.135.12.1469","article-title":"The association of HER-2\/neu amplification with breast cancer recurrence.","volume":"135","author":"Carr","year":"2000","journal-title":"Arch. Surg."},{"key":"10.1074\/mcp.R400001-MCP200_bib123","first-page":"4745","article-title":"Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.","volume":"6","author":"Ferrero-Pous","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib124","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L","article-title":"Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer.","volume":"89","author":"Platt-Higgins","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib125","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1200\/JCO.2001.19.3.645","article-title":"Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.","volume":"19","author":"Eppenberger-Castori","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib126","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0959-8049(00)00395-6","article-title":"c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease.","volume":"37","author":"Jukkola","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib127","first-page":"793","article-title":"Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.","volume":"18","author":"Gaci","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/hupa.2001.22748","article-title":"Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.","volume":"32","author":"Rudolph","year":"2001","journal-title":"Hum. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib129","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00000658-200105000-00006","article-title":"Molecular biomarkers for breast cancer prognosis: Coexpression of c-erbB-2 and p53.","volume":"233","author":"Beenken","year":"2001","journal-title":"Ann. Surg."},{"key":"10.1074\/mcp.R400001-MCP200_bib130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1023\/A:1011163211802","article-title":"C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.","volume":"12","author":"Pinto","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib131","first-page":"266","article-title":"c-erbB-2 (HER-2\/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients.","volume":"95","author":"Riou","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib132","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4081\/ejh.2001.1616","article-title":"Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.","volume":"45","author":"Horita","year":"2001","journal-title":"Eur. J. Histochem."},{"key":"10.1074\/mcp.R400001-MCP200_bib133","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.1003","article-title":"EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.","volume":"196","author":"Suo","year":"2002","journal-title":"J. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib134","first-page":"632","article-title":"Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.","volume":"62","author":"Ristimaki","year":"2002","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jso.10079","article-title":"Prognostic value of c-erbB2 expression in breast cancer.","volume":"79","author":"Tsutsui","year":"2002","journal-title":"J. Surg. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib136","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ijc.10270","article-title":"Prognostic significance of Ep-CAM AND Her-2\/neu overexpression in invasive breast cancer.","volume":"98","author":"Spizzo","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib137","first-page":"1097","article-title":"C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.","volume":"22","author":"Kato","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib138","first-page":"2493","article-title":"Multivariate analysis of bcl-2, apoptosis, P53 and HER-2\/neu in breast cancer: A short-term follow-up.","volume":"22","author":"el-Ahmady","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib139","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1309\/WMN8-VTR5-DUGF-X12L","article-title":"Current status of HER2 testing: Caught between a rock and a hard place.","volume":"116","author":"Schnitt","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib140","first-page":"2771","article-title":"Sensitivity of HER-2\/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression.","volume":"54","author":"Press","year":"1994","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib141","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/jnci\/94.11.852","article-title":"Real-world performance of HER2 testing\u2014National Surgical Adjuvant Breast and Bowel Project experience.","volume":"94","author":"Paik","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl. 1","key":"10.1074\/mcp.R400001-MCP200_bib142","first-page":"S31","article-title":"Successful quality assurance program for HER-2 testing in the NSAPB trial for Herceptin.","volume":"76","author":"Paik","year":"2002","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1074\/mcp.R400001-MCP200_bib143","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1309\/97WN-W6UX-XJWT-02H2","article-title":"Evaluation of HER-2\/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: A comparative study involving results from laboratories in 21 countries.","volume":"118","author":"Rhodes","year":"2002","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib144","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00129039-200206000-00015","article-title":"Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers.","volume":"10","author":"Arber","year":"2002","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1074\/mcp.R400001-MCP200_bib145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1309\/TMUW-G4WB-LXJ2-FUDN","article-title":"Assessment of HER-2\/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard.","volume":"116","author":"Wang","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib146","first-page":"99","article-title":"Comparison of HER-2\/neu analysis using FISH and IHC when HercepTest is scored using conventional microscopy and image analysis.","volume":"64","author":"Bloom","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1074\/mcp.R400001-MCP200_bib147","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/jcp.53.5.374","article-title":"Laboratory assessment of the status of Her-2\/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization assays.","volume":"53","author":"Wang","year":"2000","journal-title":"J. Clin. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib148","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0002-9440(10)64785-2","article-title":"Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2\/neu oncogene amplification in archival breast cancer samples.","volume":"157","author":"Tanner","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib149","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/modpathol.3880582","article-title":"Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.","volume":"15","author":"Zhao","year":"2002","journal-title":"Mod. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1309\/P40P2EAD42PUKDMG","article-title":"Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2\/neu oncogene in breast cancer.","volume":"119","author":"Gupta","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib151","first-page":"212","article-title":"A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer.","volume":"24","author":"Pawlowski","year":"2000","journal-title":"Cancer Detect. Prev."},{"key":"10.1074\/mcp.R400001-MCP200_bib152","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/clinchem\/45.8.1148","article-title":"Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.","volume":"45","author":"Bieche","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1074\/mcp.R400001-MCP200_bib153","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1200\/JCO.2001.19.10.2714","article-title":"Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message.","volume":"19","author":"Tubbs","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib154","first-page":"2406","article-title":"Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.","volume":"9","author":"Pusztai","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib155","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1038\/sj.onc.1206349","article-title":"cDNA microarray analysis of genes associated with ERBB2 (HER2\/neu) overexpression in human mammary luminal epithelial cells.","volume":"22","author":"Mackay","year":"2003","journal-title":"Oncogene"},{"key":"10.1074\/mcp.R400001-MCP200_bib156","first-page":"8235","article-title":"New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.","volume":"61","author":"Kauraniemi","year":"2001","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib157","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for high-throughput molecular profiling of tumor specimens.","volume":"4","author":"Kononen","year":"1998","journal-title":"Nat. Med."},{"key":"10.1074\/mcp.R400001-MCP200_bib158","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/labinvest.3780204","article-title":"Validation of tissue microarray technology in breast carcinoma.","volume":"80","author":"Camp","year":"2000","journal-title":"Lab. Invest."},{"key":"10.1074\/mcp.R400001-MCP200_bib159","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/1097-0320(20011001)45:2<83::AID-CYTO1149>3.0.CO;2-P","article-title":"Improved procedure for fluorescence in situ hybridization on tissue microarrays.","volume":"45","author":"Andersen","year":"2001","journal-title":"Cytometry"},{"key":"10.1074\/mcp.R400001-MCP200_bib160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jcp.55.4.315","article-title":"Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.","volume":"55","author":"Gancberg","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib161","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00129039-200306000-00016","article-title":"HER-2 analysis in tissue microarrays of archival human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization.","volume":"11","author":"O\u2019Grady","year":"2003","journal-title":"Appl. Immunohistochem. Mol. Morphol"},{"key":"10.1074\/mcp.R400001-MCP200_bib162","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/hupa.2003.60","article-title":"Evaluation of HER-2\/neu oncogene status in breast tumors on tissue microarrays.","volume":"34","author":"Zhang","year":"2003","journal-title":"Hum. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib163","first-page":"1445","article-title":"Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.","volume":"63","author":"Camp","year":"2003","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib164","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/172460080301800103","article-title":"Quantitative assessment of HER-2\/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay.","volume":"18","author":"Muller","year":"2003","journal-title":"Int. J. Biol. Markers"},{"key":"10.1074\/mcp.R400001-MCP200_bib165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/HAB-2001-103-405","article-title":"Engineered antibodies take center stage.","volume":"10","author":"Huston","year":"2001","journal-title":"Hum. Antibodies"},{"key":"10.1074\/mcp.R400001-MCP200_bib166","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0093-7754(01)90108-3","article-title":"Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.","volume":"28","author":"Hortobagyi","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib167","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00003495-200262010-00008","article-title":"Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2.","volume":"62","author":"McKeage","year":"2002","journal-title":"Drugs"},{"key":"10.1074\/mcp.R400001-MCP200_bib168","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00039-9","article-title":"Smart drugs: Tyrosine kinase inhibitors in cancer therapy.","volume":"1","author":"Shawver","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1074\/mcp.R400001-MCP200_bib169","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/sonc.2002.34054","article-title":"Trastuzumab\/chemotherapy combinations in metastatic breast cancer.","volume":"29","author":"Ligibel","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib170","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 11","key":"10.1074\/mcp.R400001-MCP200_bib171","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/sonc.2002.34051","article-title":"Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.","volume":"29","author":"Schneider","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib172","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","article-title":"Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy.","volume":"99","author":"Ozcelik","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1074\/mcp.R400001-MCP200_bib173","first-page":"5078","article-title":"HER-2-targeted therapy: Lessons learned and future directions.","volume":"9","author":"Nahta","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 13","key":"10.1074\/mcp.R400001-MCP200_bib174","first-page":"4","article-title":"Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.","volume":"25","author":"Nabholtz","year":"1998","journal-title":"Semin Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib175","first-page":"193","article-title":"Phase II pilot study of Herceptin combined with taxotere and carboplatin in metastatic breast cancer patients overexpressing the HER-2\/neu proto-oncogene: A pilot study of the UCLA network.","volume":"20","author":"Slamon","year":"2001","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib176","unstructured":"HercepTest package insert. Dako Corporation, Glostrup, Denmark."},{"key":"10.1074\/mcp.R400001-MCP200_bib177","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.1999.17.1.434","article-title":"Increased HER2 with U.S. Food and Drug Administration-approved antibody.","volume":"17","author":"Roche","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib178","first-page":"85","article-title":"Improved survival benefit from Herceptin (Trastuzumab) in patients selected by fluorescence in situ hybridization (FISH)","author":"Mass","year":"2001","journal-title":"Proc. ASCO"},{"key":"10.1074\/mcp.R400001-MCP200_bib179","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/BF02966723","article-title":"Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry.","volume":"10","author":"Ogura","year":"2003","journal-title":"Breast Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib180","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.","volume":"20","author":"Vogel","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib181","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2001.19.10.2587","article-title":"Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.","volume":"19","author":"Seidman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib182","first-page":"1340","article-title":"HER-2 testing and correlation with efficacy in Trastuzumab therapy.","volume":"16","author":"Fornier","year":"2003","journal-title":"Oncology"},{"key":"10.1074\/mcp.R400001-MCP200_bib183","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1053\/S0046-8177(03)00409-X","article-title":"Strong HER-2\/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.","volume":"34","author":"Hammock","year":"2003","journal-title":"Hum. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib184","first-page":"3","article-title":"A testing algorithm for determination of HER2 status in patients with breast cancer.","volume":"32","author":"Nichols","year":"2002","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1074\/mcp.R400001-MCP200_bib185","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00125480-200211000-00002","article-title":"Testing for HER-2\/neu in breast cancer: Is fluorescence in situ hybridization superior in predicting outcome?","volume":"9","author":"Yaziji","year":"2002","journal-title":"Adv. Anat. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib186","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","article-title":"Evaluation of HER-2\/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.","volume":"20","author":"Press","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib187","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/erc.0.0080191","article-title":"Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.","volume":"8","author":"Dowsett","year":"2001","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib188","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0093-7754(01)90125-3","article-title":"Role of adjuvant endocrine therapy in early-stage breast cancer.","volume":"28","author":"Muss","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib189","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000066224","article-title":"Prediction of response to hormonal treatment in metastatic breast cancer.","volume":"63","author":"Schmid","year":"2002","journal-title":"Oncology"},{"key":"10.1074\/mcp.R400001-MCP200_bib190","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","article-title":"Quantitative association between HER-2\/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.","volume":"95","author":"Konecny","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1074\/mcp.R400001-MCP200_bib191","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.1996.14.10.2702","article-title":"CerbB2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without ancillary lymph node metastases.","volume":"14","author":"Carlomagno","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib192","first-page":"7","article-title":"HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A southwest oncology group study.","volume":"4","author":"Elledge","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib193","first-page":"1039","article-title":"Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.","volume":"9","author":"De Placido","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib194","first-page":"97a","article-title":"Initial report of the SWOG biologicalcorrelative study of c-ERBB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with Tamoxifen alone.","volume":"17","author":"Ravdin","year":"1998","journal-title":"Proc. ASCO"},{"key":"10.1074\/mcp.R400001-MCP200_bib195","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","article-title":"Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and\/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial.","volume":"19","author":"Ellis","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib196","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0378-1119(94)00534-Y","article-title":"Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment.","volume":"159","author":"Berns","year":"1995","journal-title":"Gene"},{"key":"10.1074\/mcp.R400001-MCP200_bib197","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CBC.2000.n.002","article-title":"Taxanes for breast cancer: An evidence-based review of randomized phase II and phase III trials.","volume":"1","author":"Sparano","year":"2000","journal-title":"Clin. Breast Cancer"},{"issue":"Suppl. 16","key":"10.1074\/mcp.R400001-MCP200_bib198","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0093-7754(01)90277-5","article-title":"Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.","volume":"28","author":"Yu","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib199","first-page":"43","article-title":"HER-2 overexpression and paclitazel sensitivity in breast cancer: therapeutic implications.","volume":"11","author":"Baselga","year":"1997","journal-title":"Oncology"},{"key":"10.1074\/mcp.R400001-MCP200_bib200","first-page":"3","article-title":"The role of HER-2 oncoprotein in drug-sensitivity in breast cancer.","volume":"9","author":"Kim","year":"2002","journal-title":"Oncol. Rep."},{"key":"10.1074\/mcp.R400001-MCP200_bib201","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3816\/CBC.2000.n.020","article-title":"A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: A companion study to EORTC 10923.","volume":"1","author":"Hamilton","year":"2000","journal-title":"Clin. Breast Cancer."},{"key":"10.1074\/mcp.R400001-MCP200_bib202","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1023\/A:1011669223035","article-title":"HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.","volume":"12","author":"Di Leo","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1074\/mcp.R400001-MCP200_bib203","first-page":"1577","article-title":"Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.","volume":"7","author":"Petit","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib204","first-page":"1497","article-title":"Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.","volume":"7","author":"Harris","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib205","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/cncr.11245","article-title":"Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.","volume":"97","author":"Zhang","year":"2003","journal-title":"Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib206","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.onc.1201222","article-title":"The effect of HER-2\/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.","volume":"15","author":"Pegram","year":"1997","journal-title":"Oncogene"},{"key":"10.1074\/mcp.R400001-MCP200_bib207","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/bjc.1998.377","article-title":"Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemo-therapy in advanced breast cancer.","volume":"77","author":"Jarvinen","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib208","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.0956-5507.2003.00105.x","article-title":"Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer\u2014More common than anticipated.","volume":"14","author":"Jarvinen","year":"2003","journal-title":"Cytopathology"},{"key":"10.1074\/mcp.R400001-MCP200_bib209","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/modpathol.3880094","article-title":"Topoisomerase II alpha expression in breast cancer: correlation with outcome variables.","volume":"13","author":"Depowski","year":"2000","journal-title":"Mod. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib210","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0002-9440(10)64952-8","article-title":"Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.","volume":"156","author":"Jarvinen","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1074\/mcp.R400001-MCP200_bib211","first-page":"5345","article-title":"Amplification of HER-2\/neu and topoisomerase II alpha in primary and metastatic breast cancer.","volume":"61","author":"Tanner","year":"2001","journal-title":"Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib212","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0959-8049(02)00745-1","article-title":"Topoisomerase II-alpha (topoll) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.","volume":"39","author":"Park","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1074\/mcp.R400001-MCP200_bib213","first-page":"1107","article-title":"HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.","volume":"8","author":"Di Leo","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib214","first-page":"1061","article-title":"Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer.","volume":"8","author":"Coon","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1074\/mcp.R400001-MCP200_bib215","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/0360-3016(96)00150-2","article-title":"Evaluation of HER-2\/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study.","volume":"35","author":"Haffty","year":"1996","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"10.1074\/mcp.R400001-MCP200_bib216","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.1997.15.7.2518","article-title":"Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2\/c-neu protein.","volume":"15","author":"Yamauchi","year":"1997","journal-title":"J. Clin. Oncol."}],"container-title":["Molecular &amp; Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947620349045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947620349045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/mcp.R400001-MCP200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:03:52Z","timestamp":1761527032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947620349045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":216,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S1535947620349045"],"URL":"https:\/\/doi.org\/10.1074\/mcp.r400001-mcp200","relation":{},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Therapy in Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/mcp.R400001-MCP200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}]}}